AZD2936
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AZD2936, covering 2026-03-24 to 2026-03-24. Get the full timeline:
Most recent: Clinical Trial Update: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC [Phase 1, Phase 2]